Literature DB >> 11302764

Requirement for repair of DNA double-strand breaks by homologous recombination in split-dose recovery.

H Utsumi1, M M Elkind.   

Abstract

Utsumi, H., Tano, K., Takata, M., Takeda, S. and Elkind, M. M. Requirement for Repair of DNA Double-Strand Breaks by Homologous Recombination in Split-Dose Recovery. Radiat. Res. 155, 680-686 (2001). Split-dose recovery has been observed under a variety of experimental conditions in many cell systems and is believed to be the result of the repair of sublethal damage. It is considered to be one of the most widespread and important cellular responses in clinical radiotherapy. To study the molecular mechanism(s) of this repair, we analyzed the knockout mutants KU70-/-, RAD54-/-, and KU70-/-/RAD54-/- of the chicken B-cell line, DT40. RAD54 participates in the recombinational repair of DNA double-strand breaks (DSBs), while members of the KU family of proteins are involved in nonhomologous end joining. Split-dose recovery was observed in the parent DT40 and the KU70-/- cells. Moreover, the split-dose survival enhancement had all of the characteristics demonstrated earlier for the repair of sublethal damage, e.g., the reappearance of the shoulder on the survival curve with dose fractionation; cyclic fluctuation in cell survival at 37 degrees C; repair and no cyclic fluctuation at 25 degrees C. These results strongly suggest that repair of sublethal damage is due to DSB repair mediated by homologous recombination, and that these DNA DSBs constitute sublethal damage.

Entities:  

Mesh:

Year:  2001        PMID: 11302764     DOI: 10.1667/0033-7587(2001)155[0680:rfrodd]2.0.co;2

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  14 in total

1.  Inhibition of repair of radiation-induced damage by mild temperature hyperthermia, referring to the effect on quiescent cell populations.

Authors:  Shin-Ichiro Masunaga; Kenji Nagata; Minoru Suzuki; Genro Kashino; Yuko Kinashi; Koji Ono
Journal:  Radiat Med       Date:  2007-10-26

2.  Investigation of non-linear adaptive responses and split dose recovery induced by ionizing radiation in three human epithelial derived cell lines.

Authors:  Lorna A Ryan; Colin B Seymour; Carmel E Mothersill
Journal:  Dose Response       Date:  2009-08-06       Impact factor: 2.658

3.  Characterization of in vitro radiosensitization in mammalian cells using biomathematical modelling: implications for hypofractionated radiotherapy with a combined modality approach.

Authors:  Yuji Seo; Keisuke Tamari; Yasuo Yoshioka; Fumiaki Isohashi; Osamu Suzuki; Kazuhiko Hayashi; Yutaka Takahashi; SungJae Baek; Keisuke Otani; Kazuhiko Ogawa
Journal:  Br J Radiol       Date:  2016-03-15       Impact factor: 3.039

4.  Development and validation of a novel assay to identify radiosensitizers that target nucleophosmin 1.

Authors:  Narsimha R Penthala; Peter A Crooks; Michael L Freeman; Konjeti R Sekhar
Journal:  Bioorg Med Chem       Date:  2015-04-11       Impact factor: 3.641

5.  Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining.

Authors:  Heather J Boeckman; Kelly S Trego; John J Turchi
Journal:  Mol Cancer Res       Date:  2005-05       Impact factor: 5.852

6.  Ku-dependent non-homologous end-joining as the major pathway contributes to sublethal damage repair in mammalian cells.

Authors:  Min Liu; Solah Lee; Bailong Liu; Hongyan Wang; Lihua Dong; Ya Wang
Journal:  Int J Radiat Biol       Date:  2015-08-27       Impact factor: 2.694

7.  Response to multiple radiation doses of human colorectal carcinoma cells infected with recombinant adenovirus containing dominant-negative Ku70 fragment.

Authors:  Muneyasu Urano; Fuqiu He; Akiko Minami; C Clifton Ling; Gloria C Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-01       Impact factor: 7.038

8.  53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.

Authors:  Iris Eke; Dali Zong; Molykutty J Aryankalayil; Veit Sandfort; Michelle A Bylicky; Barbara H Rath; Edward E Graves; André Nussenzweig; C Norman Coleman
Journal:  Nucleic Acids Res       Date:  2020-02-20       Impact factor: 16.971

9.  A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Authors:  Shunsuke Meike; Tohru Yamamori; Hironobu Yasui; Masato Eitaki; Akira Matsuda; Masami Morimatsu; Masakazu Fukushima; Yasundo Yamasaki; Osamu Inanami
Journal:  Mol Cancer       Date:  2011-07-28       Impact factor: 27.401

10.  Exposure of the cytoplasm to low-dose X-rays modifies ataxia telangiectasia mutated-mediated DNA damage responses.

Authors:  Munetoshi Maeda; Masanori Tomita; Mika Maeda; Hideki Matsumoto; Noriko Usami; Kyo Kume; Katsumi Kobayashi
Journal:  Sci Rep       Date:  2021-07-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.